ロング

ZOM - Mainly based on Fundamental Analysis

486
Zomedica Pharmaceuticals (NYSEMKT:ZOM) has priced a public offering of ~133.3M common shares, together with warrants to purchase up to same number of common shares, at a combined price of $0.15/share and accompanying warrant, for expected gross proceeds of ~$20M.

Two-year warrants have an exercise price of $0.15/share.

Net proceeds will be used for the development of TRUFORMA diagnostic platform, including making milestone payments, working capital and other general corporate purposes.

Closing date is May 29

免責事項

この情報および投稿は、TradingViewが提供または推奨する金融、投資、トレード、その他のアドバイスや推奨を意図するものではなく、それらを構成するものでもありません。詳細は利用規約をご覧ください。